Overview

Study of ATR Kinase Inhibitor ART0380 as Monotherapy in Biologically Selected Advanced/Metastatic Solid Tumors Patients

Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).
Phase:
Phase 2
Details
Lead Sponsor:
Artios Pharma Ltd